research use only
Cat.No.S8304
| Related Targets | Bcl-2 Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras |
|---|---|
| Other PERK Inhibitors | GSK2606414 GSK2656157 Salubrinal ISRIB (trans-isomer) Sal003 BTdCPU CCT020312 AMG PERK 44 MK-28 |
|
In vitro |
DMSO
: 61 mg/mL
(197.51 mM)
Ethanol : 61 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 308.83 | Formula | C15H17ClN2OS |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 932986-18-0 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CCCC(=O)NCCC1=CSC(=N1)C2=CC=C(C=C2)Cl | ||
| Targets/IC50/Ki |
UPR
|
|---|---|
| In vitro |
Azoramide may have the protective effects of enhancing chaperone expression and reducing protein synthesis without inducing cytotoxicity and apoptosis. This compound may require the presence of intact IRE1 and PERK branches of the UPR to fully increase chaperone capacity. It is found to be a kind of compound with the dual property of not only boosting ER folding acutely but also activating ER chaperone capacity chronically to promote ER homeostasis. Its treatment potently protects cells against chemically-induced ER stress conditions. This chemical preserves beta cell function and survival during metabolic ER stress. Its pretreatment does not impair ER function as part of its initial action. This treatment leads to increased SERCA expression, resulting in enhanced retention of Ca+2 within the ER. It interacts with UPR pathways to promote resolution of ER stress and improve ER function.
|
| In vivo |
Azoramide improves glucose homeostasis in mice with genetic obesity and diet-induced obesity. Remarkably, this compound treatment significantly improves insulin sensitivity and glucose tolerance and beta cell function in obese mice in multiple preclinical models.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.